REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights
November 08 2017 - 4:05PM
REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage
biotechnology company seeking to improve lives through the curative
potential of gene therapy based on its proprietary NAV® Technology
Platform, today announced financial results for the third quarter
ended September 30, 2017 and recent operational highlights.
“We continue to make meaningful progress in the clinical
development of our lead product candidates, most notably with the
recent completion of dosing of the second cohort in our Phase I
clinical trial evaluating RGX-314 for the treatment of wet AMD and
completion of dosing in the first cohort in our Phase I/II clinical
trial evaluating RGX-501 for the treatment of HoFH,” said Kenneth
T. Mills, President and Chief Executive Officer of
REGENXBIO. "We remain committed to advancing our internal and
partnered gene therapy product candidates, leveraging our
proprietary NAV Technology Platform to evaluate the curative
potential of one-time administrations of gene therapy for patients
with significant unmet need. We look forward to providing
additional trial details on our lead product candidates, including
interim updates from the RGX-314 Phase I clinical trial and the
RGX-501 Phase I/II clinical trial, as part of our year-end 2017
corporate update.”
Recent Operational Highlights
- REGENXBIO completed dosing of the second cohort in the Phase I
clinical trial evaluating RGX-314 for the treatment of wet
age-related macular degeneration (wet AMD). A total of 12 patients,
from four different sites, have now been treated with RGX-314 in
the Phase I clinical trial. Based on the 12 patients dosed, we are
encouraged by the preliminary safety and tolerability profile
observed with RGX-314. Following a scheduled review by an
independent Data Safety and Monitoring Board (DSMB), the Company
expects to initiate dosing of the third cohort in the Phase I
clinical trial by the first quarter of 2018. REGENXBIO expects to
provide further details regarding the RGX-314 clinical trial,
including updates on enrollment, procedural implementation and
preliminary safety and tolerability, in the Company’s year-end 2017
corporate update scheduled to be released during the first week of
January 2018.
- Dosing of the first cohort of three patients was completed in
the Phase I/II clinical trial evaluating RGX-501 for the treatment
of homozygous familial hypercholesterolemia (HoFH). Review of data
from the first cohort has been conducted by an independent DSMB,
who has granted clearance to proceed to the next dosing cohort
based on their assessment of the safety and tolerability data. The
Company anticipates dosing of the second cohort in the trial to be
initiated prior to year-end 2017. REGENXBIO expects to provide
further details regarding the RGX-501 clinical trial, including
updates on enrollment and preliminary safety and tolerability, in
the Company’s year-end 2017 corporate update.
- REGENXBIO’s Investigational New Drug (IND) application is now
active for the Phase I clinical trial of RGX-111 for the treatment
of Mucopolysaccharidosis Type I (MPS I). Site activation in the
planned multi-center, open-label, multiple-cohort, dose-escalation
trial is underway to support recruitment and patient enrollment,
with the first patient expected to be dosed in the first half of
2018.
- REGENXBIO plans to file an IND application for RGX-121 for the
treatment of Mucopolysaccharidosis Type II (MPS II) in the fourth
quarter of 2017, which will incorporate feedback received from the
U.S. Food and Drug Administration (FDA) in its review of the IND
application for RGX-111.
- In September 2017, REGENXBIO further strengthened its
management team with the appointment of Shiva Fritsch as Senior
Vice President, Human Resources. Ms. Fritsch brings significant
expertise in the biotechnology industry, previously serving in
human resources leadership roles at Human Genome Sciences, Inc.,
the Howard Hughes Medical Institute and, most recently, at Novavax,
Inc.
- In October 2017, REGENXBIO initiated the build-out of a
state-of-the-art Research and Development facility and currently
expects to complete the build-out in 2018. The new 15,000
square foot facility supports the expansion of REGENXBIO’s internal
gene therapy research capabilities for the creation of new gene
therapy technologies and the origination of new lead product
candidates and will be adjacent to REGENXBIO’s advanced
manufacturing and analytics lab located in Rockville,
Maryland.
- As of September 30, 2017, REGENXBIO’s NAV Technology Platform
was being applied in the development of more than 20 partnered
product candidates by 10 NAV Technology Licensees. Seven of these
partnered product candidates are in active clinical
development.
- In October 2017, Shire plc announced the FDA had awarded Orphan
Drug Designation to its gene therapy candidate SHP654 for the
treatment of hemophilia A. SHP654 uses the NAV AAV8
vector.
- In September 2017, AveXis, Inc. announced that it has commenced
the pivotal trial of AVXS-101 for the treatment of spinal muscular
atrophy (SMA) Type 1. AVXS-101 uses the NAV AAV9 vector.
- Also in September 2017, Audentes Therapeutics, Inc. announced
dosing of the first patient in the Phase I/II clinical trial
evaluating AT132 for the treatment of X-linked myotubular myopathy.
AT132 uses the NAV AAV8 vector.
- In August 2017, Dimension Therapeutics, Inc., which was
subsequently acquired by Ultragenyx Pharmaceutical Inc., announced
dosing of the first patient in the Phase I/II clinical trial of
DTX301 for the treatment of ornithine transcarbamylase (OTC)
deficiency. DTX301 uses the NAV AAV8 vector.
Financial Results
Cash, cash equivalents and marketable securities were $191.1
million as of September 30, 2017, compared to $159.0 million as of
December 31, 2016. Revenues were $1.3 million for the three months
ended September 30, 2017, compared to $0.1 million for the three
months ended September 30, 2016. Total operating expenses were
$22.6 million for the three months ended September 30, 2017,
compared to $18.8 million for the three months ended September 30,
2016. Net loss was $20.7 million, or $0.67 net loss per basic and
diluted common share, for the three months ended September 30,
2017, compared to $18.2 million, or $0.69 net loss per basic and
diluted share, for the three months ended September 30, 2016.
Financial Guidance
REGENXBIO continues to expect full-year 2017 cash burn to be
between $75 million and $80 million, which will support the
continued development of its lead product candidate programs.
Full-year 2017 cash burn guidance excludes the effect of
REGENXBIO’s previously announced underwritten public offering of
common stock in March 2017, which resulted in aggregate net
proceeds to REGENXBIO of approximately $81.5 million, after
deducting underwriting discounts and commissions and offering
expenses.
Conference Call Information
In connection with the earnings release, REGENXBIO will host a
conference call today at 4:30 p.m. ET. To access the live call
by phone, dial (855) 422-8964 (domestic) or (210) 229-8819
(international), and enter the passcode 96009722. To access a live
or recorded webcast of the call, please visit the “Investors”
section of the REGENXBIO website
at www.regenxbio.com. The recorded webcast will be available
for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO’s NAV® Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV
Technology Platform in the development of a broad pipeline of
candidates in multiple therapeutic areas.
Forward Looking Statements
This press release includes “forward-looking statements,” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of
1934, as amended. These statements express a belief,
expectation or intention and are generally accompanied by words
that convey projected future events or outcomes such as “believe,”
“may,” “will,” “estimate,” “continue,” “anticipate,” “design,”
“intend,” “expect,” “could,” “plan,” “potential,” “predict,”
“seek,” “should,” “would” or by variations of such words or by
similar expressions. The forward-looking statements include
statements relating to, among other things, statements about
REGENXBIO’s future operations, costs and cash flow. REGENXBIO
has based these forward-looking statements on its current
expectations and assumptions and analyses made by REGENXBIO in
light of its experience and its perception of historical trends,
current conditions and expected future developments, as well as
other factors REGENXBIO believes are appropriate under the
circumstances. However, whether actual results and
developments will conform with REGENXBIO’s expectations and
predictions is subject to a number of risks and uncertainties,
including the timing of enrollment, commencement and completion of
REGENXBIO’s clinical trials; the timing and success of preclinical
studies and clinical trials conducted by REGENXBIO and its
development partners, the timely development and launch of new
products, the ability to obtain and maintain regulatory approval of
product candidates, the ability to obtain and maintain intellectual
property protection for product candidates and technology, trends
and challenges in the business and markets in which REGENXBIO
operates, the size and growth of potential markets for product
candidates and the ability to serve those markets, the rate and
degree of acceptance of product candidates, and other factors, many
of which are beyond the control of REGENXBIO. Refer to the
“Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” sections of
REGENXBIO’s Annual Report on Form 10-K for the year ended December
31, 2016 and comparable “risk factors” sections of REGENXBIO’s
Quarterly Reports on Form 10-Q and other filings, which have been
filed with the U.S. Securities and Exchange Commission (SEC) and
are available on the SEC’s website at www.sec.gov. All of the
forward-looking statements made in this press release are expressly
qualified by the cautionary statements contained or referred to
herein. The actual results or developments anticipated may not be
realized or, even if substantially realized, they may not have the
expected consequences to or effects on REGENXBIO or its businesses
or operations. Such statements are not guarantees of future
performance and actual results or developments may differ
materially from those projected in the forward-looking statements.
Readers are cautioned not to rely too heavily on the
forward-looking statements contained in this press release.
These forward-looking statements speak only as of the date of this
press release. REGENXBIO does not undertake any obligation,
and specifically declines any obligation, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
|
REGENXBIO INC.CONSOLIDATED
BALANCE SHEETS(unaudited)(in
thousands, except per share data) |
|
|
|
September 30, 2017 |
|
|
December 31, 2016 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and
cash equivalents |
|
$ |
59,884 |
|
|
$ |
24,840 |
|
Marketable securities |
|
|
106,778 |
|
|
|
64,714 |
|
Accounts
receivable |
|
|
884 |
|
|
|
1,032 |
|
Prepaid
expenses |
|
|
3,225 |
|
|
|
1,775 |
|
Other
current assets |
|
|
1,390 |
|
|
|
1,010 |
|
Total
current assets |
|
|
172,161 |
|
|
|
93,371 |
|
Marketable
securities |
|
|
24,485 |
|
|
|
69,412 |
|
Property and equipment,
net |
|
|
11,548 |
|
|
|
9,324 |
|
Restricted cash |
|
|
225 |
|
|
|
225 |
|
Other assets |
|
|
836 |
|
|
|
400 |
|
Total
assets |
|
$ |
209,255 |
|
|
$ |
172,732 |
|
Liabilities and
Stockholders’
Equity |
|
|
|
|
|
|
|
|
Current
liabilities |
|
|
|
|
|
|
|
|
Accounts
payable |
|
$ |
2,594 |
|
|
$ |
1,543 |
|
Accrued
expenses and other current liabilities |
|
|
10,805 |
|
|
|
8,126 |
|
Total
current liabilities |
|
|
13,399 |
|
|
|
9,669 |
|
Deferred rent, net of
current portion |
|
|
1,205 |
|
|
|
1,326 |
|
Total
liabilities |
|
|
14,604 |
|
|
|
10,995 |
|
Stockholders’
equity |
|
|
|
|
|
|
|
|
Preferred
stock; $0.0001 par value; 10,000 shares authorized, and no
shares issued and outstanding at September 30, 2017 and
December 31, 2016 |
|
|
— |
|
|
|
— |
|
Common
stock; $0.0001 par value; 100,000 shares authorized at
September 30, 2017 and December 31, 2016; 31,109 and 26,477
shares issued and outstanding at September 30, 2017 and
December 31, 2016, respectively |
|
|
3 |
|
|
|
3 |
|
Additional paid-in capital |
|
|
366,960 |
|
|
|
276,354 |
|
Accumulated other comprehensive loss |
|
|
(553 |
) |
|
|
(33 |
) |
Accumulated deficit |
|
|
(171,759 |
) |
|
|
(114,587 |
) |
Total
stockholders’ equity |
|
|
194,651 |
|
|
|
161,737 |
|
Total
liabilities and stockholders’ equity |
|
$ |
209,255 |
|
|
$ |
172,732 |
|
|
|
REGENXBIO INC.CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS(unaudited)(in thousands,
except per share data) |
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
|
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
License
revenue |
|
$ |
1,335 |
|
|
$ |
65 |
|
|
$ |
8,345 |
|
|
$ |
2,638 |
|
Reagent
sales |
|
|
— |
|
|
|
47 |
|
|
|
— |
|
|
|
213 |
|
Grant
revenue |
|
|
1 |
|
|
|
13 |
|
|
|
8 |
|
|
|
42 |
|
Total
revenues |
|
|
1,336 |
|
|
|
125 |
|
|
|
8,353 |
|
|
|
2,893 |
|
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs of
revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Licensing
costs |
|
|
683 |
|
|
|
13 |
|
|
|
2,085 |
|
|
|
528 |
|
Costs of
reagent sales |
|
|
— |
|
|
|
22 |
|
|
|
6 |
|
|
|
101 |
|
Research
and development |
|
|
12,518 |
|
|
|
12,560 |
|
|
|
43,054 |
|
|
|
29,423 |
|
General
and administrative |
|
|
9,444 |
|
|
|
6,200 |
|
|
|
22,421 |
|
|
|
17,848 |
|
Other
operating expenses (income) |
|
|
— |
|
|
|
(2 |
) |
|
|
74 |
|
|
|
(136 |
) |
Total
operating expenses |
|
|
22,645 |
|
|
|
18,793 |
|
|
|
67,640 |
|
|
|
47,764 |
|
Loss from
operations |
|
|
(21,309 |
) |
|
|
(18,668 |
) |
|
|
(59,287 |
) |
|
|
(44,871 |
) |
Other
Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment income |
|
|
603 |
|
|
|
514 |
|
|
|
2,115 |
|
|
|
1,512 |
|
Total
other income |
|
|
603 |
|
|
|
514 |
|
|
|
2,115 |
|
|
|
1,512 |
|
Net
loss |
|
$ |
(20,706 |
) |
|
$ |
(18,154 |
) |
|
$ |
(57,172 |
) |
|
$ |
(43,359 |
) |
Other
Comprehensive Income (Loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain (loss) on available-for-sale securities, net
of reclassifications of $479 and $20 for the nine months ended
September 30, 2017 and 2016, respectively |
|
|
93 |
|
|
|
332 |
|
|
|
(521 |
) |
|
|
1,572 |
|
Total
other comprehensive income (loss) |
|
|
93 |
|
|
|
332 |
|
|
|
(521 |
) |
|
|
1,572 |
|
Comprehensive loss |
|
$ |
(20,613 |
) |
|
$ |
(17,822 |
) |
|
$ |
(57,693 |
) |
|
$ |
(41,787 |
) |
Basic and diluted net
loss per common share |
|
$ |
(0.67 |
) |
|
$ |
(0.69 |
) |
|
$ |
(1.94 |
) |
|
$ |
(1.64 |
) |
Weighted-average basic
and diluted common shares |
|
|
30,940 |
|
|
|
26,469 |
|
|
|
29,440 |
|
|
|
26,386 |
|
|
|
CONTACT:
Investors Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com
Media Adam Pawluk, 202-591-4063
apawluk@jpa.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024